Prescient Therapeutics (ASX:PTX) makes progress in March 2023 quarter
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its...
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Life science stocks have suffered heavily in 2022 due to investors shifting out of risk...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell &...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
CEO and MD of Prescient Therapeutics, Steven Yatomi-Clarke, held a briefing where he outlined the...
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix,...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.